Ratings Hvsen Biotechnology Co., Ltd.

Equities

300871

CNE1000047H6

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
14.05 ^CNY	+0.64%		-0.07%	-2.84%

Apr. 25	Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023	CI
Apr. 24	Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's profit outlook over the next few years is a strong asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

With a 2024 P/E ratio at 34.69 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HVSEN BIOTECHNOLOGY CO., LTD.	-2.84%	317M	-
ZOETIS INC.	-15.35%	76.23B	B+
ELANCO ANIMAL HEALTH INCORPORATED	-9.19%	6.67B	B-
VIRBAC	-1.11%	3.21B	B-
VIMIAN GROUP AB	+6.08%	1.52B	-
JINYU BIO-TECHNOLOGY CO., LTD.	-15.13%	1.37B	B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-25.63%	1.24B	C-
VETOQUINOL SA	-7.62%	1.21B	-
WUHAN KEQIAN BIOLOGY CO.,LTD	-10.84%	1.17B	-
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-.--%	1.05B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes